NanoPac

Summary

This study focuses on patients who have pancreatic cancer that cannot be removed with surgery and who have already received standard of care treatment (including IV chemotherapy). The purpose of the study is to determine whether the use of an investigational drug called NanoPac helps kill cancer cells in patients with pancreatic cancer. Researchers also aim to identify the dose of NanoPac that is best tolerated and causes the least side effects when injected directly into the tumor in the pancreas. NanoPac is made of very small particles of another drug called paclitaxel, which is a chemotherapy drug approved by the U.S. Food and Drug Administration for other types of cancer. The use of Nanopac in this study is investigational.


Inclusion Criteria

  • Signed informed consent;
  • Age ≥18 years;
  • Histologically/cytologically confirmed locally advanced pancreatic adenocarcinoma; at least one lesion with a diameter of at least 1.5 cm but no more than 6 cm as documented via imaging (within 6 weeks of Screening);
  • Subject not a candidate for surgery;
Show more

Study Location(s)

Cedars-Sinai Cancer at SOCC : Liliana Bancila

More about this Clinical Trial

Full Title

NANOPAC-2016-05: Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects with Locally Advanced Pancreatic Adenocarcinoma

Details
Disease Type/Condition

Pancreatic Biliary Diseases, Pancreatic Diseases

Principal Investigator

Lo, Simon

Co-Investigators

Andrew Hendifar, Richard Tuli, Srinivas Gaddam

Age Group

Adult

Phase

II

IRB Number

Pro00049989

ClinicalTrials.gov ID

NCT03077685

Key Eligibility
ClinicalTrials.gov

Contact
Name

Liliana Bancila

Phone
+1 310-423-3872
Email
BancilaL@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Pancreatic Biliary Diseases, Pancreatic Diseases

Principal Investigator

Lo, Simon

Age Group

Adult

Phase

II

IRB Number

NANOPAC-2016-05

ClinicalTrials.gov ID

NCT03077685

Key Eligibility
ClinicalTrials.gov

Contact
Name

Liliana Bancila

Phone
+1 310-423-3872
Email
BancilaL@cshs.org
Want to join the study or
learn more?